Full Press Release Details
Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences
California, October 9, 2019 - Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading
temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced its Board of Directors
has unanimously authorized a share repurchase program, under which Cryoport may repurchase up to $15 million of its outstanding
Cryoport CEO, said, "The authorization of the share repurchase program is a result of our constant focus on shareholder
return and effective capital allocation. The authorization of this repurchase program demonstrates the Board's confidence in our
business model, our financial performance, and our commitment to delivering value to our stakeholders. We plan to opportunistically
repurchase shares of our common stock, while maintaining ample liquidity to support our growth organically and through potential
may be made from time to time on the open market or otherwise, in such quantities, at such prices, and in such manner as determined
by management at its discretion and will depend on a number of factors, including the market price of Cryoport's common
stock, general market and economic conditions, and applicable legal requirements. The repurchase program will expire on December
31, 2020 and may be extended, suspended, modified or discontinued at any time. The company does not expect to incur debt to fund
the share repurchase program.
Upcoming Investor Conferences
Cryoport will be presenting at the
following upcoming investor road shows or conferences:
(Nasdaq: CYRX) is the world's premier provider of temperature-controlled logistics solutions for the life sciences industry, serving
the Biopharma, Reproductive Medicine and Animal Health markets. Our mission is to support life and health on earth by providing
reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and
dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information
technology; smart, sustainable cold chain logistics; and biostorage/biobanking services, Cryoport helps its customers advance
life sciences research and deliver vaccines, medicines, IVF treatments and life-saving advanced therapies in over 100 countries
around the world. For more information, visit www.cryoport.com or follow @cryoport on Twitter at www.twitter.com/cryoport
in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes,
beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results
could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in
the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The
Company's business could be affected by a number of other factors, including the risk factors listed from time to time in
the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed
with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press
release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in
Todd Fromer/Elizabeth